Ir para o conteúdo
Global sound
The Bio Report

The Bio Report

Slowing Disability in MS

· 29 min · Episódio 171

Notas do episódio

Most existing therapies for multiple sclerosis do a good job of reducing relapses and inflammatory activity, but they largely fail to stop the slow neurodegeneration that drives long-term disability, especially in progressive forms of the disease. Immunic Therapeutics is trying to reshape the treatment landscape for multiple sclerosis with its experimental once-daily oral therapy, designed not only to curb inflammation and relapses but also to tackle the neurodegeneration that silently drives disability progression in both relapsing and progressive forms of MS. Daniel Vitt, CEO of Immunic, discusses how the company’s experimental MS therapy works, how it may protect neurons from cell death, and the potential for its dual mechanism of action to change the treatment landscape.

Site: thebioreport.podbean.com

Ao vivo, última hora: 6.913 músicas em 3.075 rádios de 129 países

Descubra o mundo pelo rádio

Mais formas de descobrir (9)

Ouviu algo legal? Salve ou abra direto no Spotify.

CommunityContinuar ouvindo